

EPIX MEDICAL INC  
Form 8-K  
June 07, 2004

# SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

---

## FORM 8-K

### CURRENT REPORT

Pursuant to Section 13 or 15(d)  
of the Securities Exchange Act of 1934

---

Date of Report (Date of earliest event reported): **June 7, 2004**

## EPIX Medical, Inc.

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other  
jurisdiction of  
incorporation)

**000-21863**  
(Commission  
File Number)

**04-3030815**  
(IRS Employer  
Identification No.)

**71 Rogers Street**  
**Cambridge, Massachusetts 02142**

(Address of principal executive offices) (Zip Code)

Edgar Filing: EPIX MEDICAL INC - Form 8-K

Registrant's telephone number, including area code: **(617) 250-6000**

---

---

**Item 5. Other Events.**

On June 7, 2004, EPIX Medical, Inc. issued a press release announcing that MS-325, its new intravenous blood pool contrast agent for Magnetic Resonance Angiography (MRA), has been submitted for marketing approval in the European Union by its worldwide marketing partner, Schering AG, Germany. A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1.

**Item 7. Financial Statements and Exhibits.**

(c) The following exhibit is furnished with this report:

Exhibit Number	Description
99.1	Press Release dated June 7, 2004.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

EPIX Medical, Inc.  
(Registrant)

Date: June 7, 2004

/s/

Peyton J. Marshall  
Peyton J. Marshall  
*Senior Vice-President,  
Finance and Administration,  
Chief Financial Officer*